NEW YORK – Bio-Techne on Wednesday said that the General Services Administration (GSA) has awarded a 10-year reimbursement contract to its Exosome Diagnostics laboratory for the ExoDx Prostate (EPI) test.
The contract took effect today, providing 9 million additional men access to the urine-based genomic EPI test for early detection of prostate cancer, the firm said.